WO1992020352A1 - Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it - Google Patents
Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it Download PDFInfo
- Publication number
- WO1992020352A1 WO1992020352A1 PCT/BG1991/000001 BG9100001W WO9220352A1 WO 1992020352 A1 WO1992020352 A1 WO 1992020352A1 BG 9100001 W BG9100001 W BG 9100001W WO 9220352 A1 WO9220352 A1 WO 9220352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- sodium thiosulphate
- microorganisms
- diseases caused
- acid
- Prior art date
Links
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 title claims abstract description 33
- 239000002253 acid Substances 0.000 title claims abstract description 32
- 239000004133 Sodium thiosulphate Substances 0.000 title claims abstract description 29
- 235000019345 sodium thiosulphate Nutrition 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 18
- 244000005700 microbiome Species 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 150000007513 acids Chemical class 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005864 Sulphur Substances 0.000 claims abstract description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 6
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000003780 insertion Methods 0.000 abstract description 2
- 230000037431 insertion Effects 0.000 abstract description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- -1 chemical compounds sodium thiosulphate Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Definitions
- antibiotics At present for treatment of these diseases are used antibiotics, sulphamides, organic compounds of arsenic, bismuth etc; They all exert a positive impact for favourable running of the healing process but their efficiency is some times unsufficient and to some extent they may have a harmful effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The means for treatment of diseases caused by microorganisms represents a mixture of aqueous solutions of sodium thiosulphate and of weak acids in particular ascorbinic. The method for preparing and use of this means for treatment of diseases caused by microorganisms comprises the mixing of its components under sterile conditions and at ambient temperature whereby in case of intravenal administering, it is effected as preferred embodiment in a syringe by consecutive aspiration of the components and for local administering in a suitable vessel. The means represents a mixtures of two components whereby in the organism are introduced beside the non-reacted excess of sodium thiosulphate and the obtained by the mixing sodium salt of the acid, sulphur and NaHSO3. Their preparation and insertion in the organism provides for a rational and original way of introducing these substances as well as a complete interaction with internal processes in the organism in order to achieve a vigourous therapeutic effect. The tests which have been performed show that the means has a wide range of action against disease causing microorganisms while being practically harmless.
Description
Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it
The invention refers to a means for treatment of diseases caused by microorganisms and a method for its preparation and use. It can be applied for treatment of persons and animals in diseases caused by microorganisms(bacteria,viruses).
At present for treatment of these diseases are used antibiotics, sulphamides, organic compounds of arsenic, bismuth etc; They all exert a positive impact for favourable running of the healing process but their efficiency is some times unsufficient and to some extent they may have a harmful effect.
On the other side there are known also the chemical compounds sodium thiosulphate used as antidote in some kinds of intoxications as well as ascorbinic acid which is needed by the organisms and used for treatment of different morbid affections. However both compounds have an unsufficient efficiency in the independent administering for treatment of diseases caused by microorganisms.
The object of the invention is to provide for a means for tre ting of diseases caused by microorganisms in human beings and animals and a method for its preparation and use whereby the means ought to be practically harmless in observing curative doses and they should have a high healing effect.
The means with which is attained this object in treating dirseaseε caused by microorganisms represents a mixture of aqueous solutions of sodium thiosulphate and of weak acids in particular organic acids which are harmless for organisms and in reaction with sodium thiosulphate they form sodium sal of the acid, sulphur and NaHSO3. The amount of sodium thiosul
phate in the mixture with regard to the amount of weak acid is equal or more than the amount of sodium thiosulphate according to the respective stoichometric equation that is sufficient for complete reacting between both components. When the quantity of sodium thiosulphate is considerably more than the needed for the reaction it is established a significant excess of it in the obtained mixture.
According to a prefered embodiment in the means for treatment of diseases caused by microorganisms is used as a weak acid ascorbinic acid C6H8O6 , whereby the ratio of amount of sodium thiosulphate Na2S2O3·5H2O to the amount of ascorbinic acid C6H8O6 is not less than 1 : 0.7. Sodium Thiosulphate in the mixture can be with or without 5 molecules H2O. A wide range of therapeutic effect is shown by the means in which the ratio of the amount of sodium thiosulphate
Na2S2O3·5H2O to the amount of ascorbinic acid C6H8O6 is 4:1.
The method for preparation and use of the means for treatment of diseases caused by microorganisms consists in that its components - aqueous solutions of sodium thiosulphate and of weak acids are mixed at ambient temperature and sterile conditions until are obtained the sodium salt of the acid, sulphur and NaHSO3 immediately before administering it externally or intravenally.
Usually the mixing of both components is effected in a syringe by consecutive inserting of aqueous solutions of sodium thiosulphate and of weak acids or mixing of solutions of them before the needle in case where are used systems. The basic requirement for injecting immediately after obtaining the mixture should be observed strictly since if the obtained mixture is retained a longer time sulphur particles are increasing which results in a decrease of efficiency and eventually it can conduct to unwanted results. In order to avoid it it is purposeful to use technical means for fixing
the period of mixing and to employ syringes with filters.
In the multiple experiments following the rule according to the proposed method the mixture to be inserted in the blood without retaining immediately after its preparing there have not been observed any harmful after-effects so that the means is practically innocuous in the administered therapeutic dose
According to the method in the reaction proceeding between the aqueous solutions of sodium thiosulphate and weak acids in particular ascorbinic acid which is prefered and is satisfying all requirements is obtained sodium salt of ascorbinic acid, sulphur and NaHSO3. In the blood besides these three substances are entering and considerable amounts of sodium thiosulphate since it is prefered its quantity to be in excess of the required for the complete running of the reaction in mixing both components.
The experiments show also that a mixture of four parts 10%-aqueous solution of sodium thiosulphate and one part 10%-aqueous solution of ascorbining acid has a very high therapeu tic effect and a wide range of action.
The means for treatment of diseases caused by microorganisms and the method for its preparation and use achieve in a ratio nal and original way the problem of introducing sodium salt of ascorbinic acid, colloidic sulphur and sodium bisulphite as well of sodium thiosulphate in excess into the blood with therapeutic purpose without bringing harmful after-effects.
The proposed means and method for its preparation and use are elucidated more in detail by following examples:
A. Test for harmfulness, A mixture of four parts of 10%-aq. solution of sodium thiosulphate and one part of 10%- aq. solution of ascorbinic acid prepared at ambient temperature and sterile conditions is used immediately after mixing usually
within a three minute period,
1. Tests for determining of ID-50. By means of multiple serial experiments of mice with intravenal insertion of the preparation it has been determined that the dose LD-50 is between 1.28 and 1.76 g per kg of alive weight.
2. Tests for sharp tolerance of rabbits. In intravenal administering of a dose of 200 mg per 1 kg alive weight it has been established that there are no damages.
3. Tests with white rats for determining the influence of the preparation on blood pressure, cardiac frequence, frequence of breathing in intravenal administering of three dif* ferent doses: 50 mg, 100 mg and 200 mg per kg alive weight. Only in the case of inserting 200 mg for kg alive weight it was observed a slight acceleration of breathing during half to one minute only in the moment of injecting being transitional. With the other doses there were no changes. 4. Tests with dogs , race "Beagle" with weight 10 to 15 kg. Each day were administered at once doses of 50 mg and 100 mg per kg alive weight during 30 days. Testing was carried out on the 7th day and on the 48th hour of the 30th day after administering. Following results were obtained: haematological data - no deviations from standard blood analysis and blood curdling. Biochemical data: there are no changes in alkaline
- equilibrium and in results from proteinic, carbohydratie and lipidic exchange and in electrolyte contents(sodium, potassium, phosphor, fluorides). There are also no data for modifications in liver and kidney function.
B. Test for treatment of diseases by local administering.
A mixture is used consisting of four parts of 10%-aqueous solution of sodium thiosulphate and one part of 10%-aq. solution of ascorbinic acid( in the second case with citric acid) which was prepared in mixing at ambient temperature .
and under sterile conditions. It is administered immediately in the period from 3 to 5 min. The following experiments have been carried out directly after mixing:
1. For keratite from human herpes virus type I on rabbits with clearly expressed viral damages. With drops in the eyes was achieved a complete healing.
2. Treatment of chronic endometrites of cows with an aqueous solution of Na2S2O3 ·5 H2O and citric acid. Complete healing
3. Treatment of chlamidiose of human beings - all healed. 4. Treatment of herpetic keratite and zoster ophtalmica in human beings. Treatment of eye damages - all healed.
C. Tests for treatment by intravenal administering. Of great practical and theoretical interest are the tests carried out by intravenal administering of a mixture comprising four part of 10%- aqueous solution of sodium thiosulphate and one part of 10% aqueous solution of ascorbinic acid. Mixing is performed at ambient temperature and under sterile conditions and it is administered immediately in the interval of 30 to 40 s. The therapeutic dose used is of 40 mg per kg alive weight whi le the sodium thiosulphate is 32 mg and ascorbinic acii-8 mg. Tests have been performed immediately after mixing. Data show that the chemiotherapeutic index -Dosis tolerantia to Dosis Curatica is very favourable.
Following tests were carried out:
1. Tests with rabbits, infected by beef herpes virus type I. All treated rabbits have been healed.
2. Treatment of calves suffering from gastroenterite(colibacteriose) with a mixed infection. 83% habe been healed. It is stated that the died calves were treated too late.
3. Treatment of rams suffering from Brucella ov. by three- and five-time injecting. Complete healing has been achieved.
4. Treatment of mice malaria. After one to two-time treatment it is observed a considerable prologation of mice life with evident decrease in index of erythrocytic parasitizing. The experiment has been discontinued.
6. Treatment of sick persons suffering from AIDS, and carriers of virus HIV. Good clinical results have been attained as well as temporary disappearing of HIY from the blood.However the therapeutic treatments have not yet been terminated and no definite results are available at present.
Claims
1. Means for treatment of diseases caused by microorganisms, characterized in that it represents a mixture of aqueous solutions of sodium thiosulphate and of weak acids in particular organic acids which during the process of reaction with sodium thiosulphate are forming sodium salt of the acid, sulphur and NaHSO3 whereby the amount of sodium thiosulphate with respect to the amount of weak acids is equal or larger than the amount determined according to the respective stochiometric equation.
2.Means for treatment of diseases caused by microorganisms according to claim 1 , characterized in that as weak acid is used ascorbinic acid C6H8O6 whereby the ratio of amount of sodium thiosulphate Na2S2O3;5 H2O to amount of ascorbinic acid C6H8O6 is not less than 1 : 0.7.
3. Means for treatment of diseases caused by microorganisms according to claims 1 and 2, characterized in that it represents a mixture consisting of four parts of 10%-aqueous solution of sodium thiosulphate Na2S2O3. 5 H2O and one part of 10%- aqueous solution of ascorbinic acid C6H8O6.
4. Method for preparing and use of this means for treatment of diseases caused by microorganisms according to claims 1 ,
2, 3, characterized in that the aqueous solutions of sodium thiosulphate and of the weak acids are mixed until are obtained the sodium salt of the acids, sulphur and NaHSO3 at ambient temperature and under sterile conditions immediately before administering the mixture externally or intravenally.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG94408 | 1991-05-13 | ||
| BG9440891 | 1991-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992020352A1 true WO1992020352A1 (en) | 1992-11-26 |
Family
ID=3923733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BG1991/000001 WO1992020352A1 (en) | 1991-05-13 | 1991-06-19 | Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU8051891A (en) |
| WO (1) | WO1992020352A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| US6664239B2 (en) | 1997-05-06 | 2003-12-16 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6756369B2 (en) | 1997-05-06 | 2004-06-29 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6884784B1 (en) | 1997-05-06 | 2005-04-26 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2445679A1 (en) * | 1973-09-25 | 1975-03-27 | Merieux Inst | NEW IMMUNITY STIMULATING DRUGS |
| US4474759A (en) * | 1982-07-22 | 1984-10-02 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| US4929378A (en) * | 1986-07-03 | 1990-05-29 | Takeda Chemical Industries, Ltd. | Bath preparation |
-
1991
- 1991-06-19 WO PCT/BG1991/000001 patent/WO1992020352A1/en active Application Filing
- 1991-06-19 AU AU80518/91A patent/AU8051891A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2445679A1 (en) * | 1973-09-25 | 1975-03-27 | Merieux Inst | NEW IMMUNITY STIMULATING DRUGS |
| US4474759A (en) * | 1982-07-22 | 1984-10-02 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| US4929378A (en) * | 1986-07-03 | 1990-05-29 | Takeda Chemical Industries, Ltd. | Bath preparation |
Non-Patent Citations (4)
| Title |
|---|
| Dialog Information Services, File 351, World Patent Index 81-91, Dialog accession no. 007066043, Ishimoto T: "Antimycotic agent without irritant effect or strong smell contg. thiophosphate,alum and acid", DE 3629385, A, 870305, 8710 (Basic) * |
| Dialog Information Services, File 351, World Patent Index 81-91, Dialog accession no. 007315007, Kaza Vaskhnil veter: "Salt solution veterinary treat calf; contain supplementary salt ascorbic acid increase therapeutic efficiency", SU 1246448, A, 870223, 8744 (Basic) * |
| National Library of Medicin, database Medline, accession no. 89294359, Margulis FB et al: "Use of sodium thiosulfate with fibrinolysin and endolypmphatic antibacterial therapy in the com- plex treatment of suppurative wounds", Klin Khir 1989;(1):56 * |
| National Library of Medicin, database Medline, accession no. 91239479, Starostenko EV et al: "The use of antioxidants in the complex therapy of patients with infiltrating pulmonary tuberculosis", Probl Tuberk 1991; (1): 9-11 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| US6664239B2 (en) | 1997-05-06 | 2003-12-16 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6756369B2 (en) | 1997-05-06 | 2004-06-29 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6884784B1 (en) | 1997-05-06 | 2005-04-26 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8051891A (en) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327642T2 (en) | METHOD FOR TREATING VIRAL INFECTIONS | |
| DE3486150T2 (en) | COMPOSITIONS FOR THE PROPYLACTIC TREATMENT OF OSTEITIS AND OSTEOMYELITIS. | |
| WO1992020352A1 (en) | Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it | |
| US4499084A (en) | Ara-A Antiviral composition and method of administering the same | |
| RU2108797C1 (en) | Method of dna-base antiviral preparation preparing | |
| EP0978289A1 (en) | Virucide drug containing iodine | |
| EP0561145B1 (en) | Use of a chemicallly stabilized chlorite matrix for the manufacture of medicaments for the treatment of HIV infections | |
| DE69117923T2 (en) | PHARMACEUTICAL COMPOSITIONS FOR AIDS TREATMENT | |
| RU2232501C2 (en) | Method for increasing natural resistance in animals | |
| RU2192870C1 (en) | Antiviral composition, method of its active component preparing and method of treatment of hiv-infected patients with said composition | |
| RU2256460C2 (en) | Method for treating inspecific bronchopneumonia in calves | |
| RU2058791C1 (en) | Stimulating agent of reproductive capability in warm-blooded animal | |
| RU2010565C1 (en) | Preparation and methods for treating and prophylaxis of acute gastroenteric diseases of new-born calves | |
| CA1257203A (en) | Dialysis with monophosphoryl lipid a | |
| RU2395278C1 (en) | Method of obtaining complex medication for prevention and treatment of metabolism pathology and malfunctions of immune system in animals | |
| RU2119334C1 (en) | Anthelmintic agent | |
| Driver | Effects of Hexylresorcinol and Other Agents on the Absorption of Sugars, Chloride and Sulfate from the Alimentary Tract | |
| RU2098102C1 (en) | Medicinal agent for asiderotic anemia treatment in children | |
| RU1805959C (en) | Method of controlling viral gastroenteric disease in pigs | |
| RU2200547C2 (en) | Preparation for treating hepatosis in animals | |
| RU2220717C2 (en) | Preparation for treatment of canine parvoviral enteritis and method for its application | |
| RU1787437C (en) | Agent for prophylaxis and treatment fishes with aeromonosis | |
| Al-Khayat et al. | Chelation of Ambilhar with Calcium and Magnesium | |
| WO1984001505A1 (en) | Opsonins in peritoneal dialysis | |
| RU94031512A (en) | Method for production and medium for storage of vascular homograft preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA FI HU JP PL RO SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
| CFP | Corrected version of a pamphlet front page | ||
| COP | Corrected version of pamphlet |
Free format text: FORM PCT/ISA/210 (EXTRA SHEET), ADDED |
|
| CR1 | Correction of entry in section i | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |